

Nanolive's expansion in the USA: Jonathan Day appointed as General Manager

Cambridge, Massachusetts, United States — October 6th, 2022 - Nanolive SA, a leading live cell imaging and analysis company, is pleased to announce that Jonathan Day is appointed as General Manager for Nanolive in North America as of October the 3rd, 2022.

With a proven track record of successful commercial achievements as a life-sciences Vice President both at Standard BioTools and Agena Bioscience, Jonathan possesses extensive knowledge in sales, market expansion, and the execution of product launches.

"I am honored to have been given this exceptional opportunity to support Nanolive's global growth and to be part of the expansion of this unique label-free imaging and analysis solution. Building, developing and leading the US team will be an important part of my role to ensure Nanolive becomes the industry leader in label-free live cell analysis."

In his new role as the General Manager at Nanolive's US headquarters, Jonathan will oversee all sales, services, and market expansion in North America. His exceptional history of achievements across multiple different companies will bring an award-winning mentality to Nanolive, while his excellent team building, development, and leadership skills will ensure Nanolive establishes long-term, profitable relationships with customers. He will work closely with all key stakeholders to enhance the commercial success of Nanolive's portfolio, by developing value-added, customer-centric sales strategies, and partnering with top key customers and prospects as their preferred vendor to increase revenue.

"Nanolive is delighted to have secured a person of Mr. Day's remarkable caliber and international experience to be the next General Manager for North America" says Dr. Yann Cotte, Nanolive's co-founder and CEO. "We look forward very much to working closely with Mr. Day to drive our growth and support our new and existing customers in the United States."



Jonathan Day

About Nanolive SA

Nanolive SA is a Swiss company pioneer in the development and commercialization of innovative label-free, non-invasive live cell imaging and state-of-the-art digital analytical solutions. Nanolive's breakthrough live cell imaging and analysis platforms accelerate innovation in growth industries such as drug discovery and cell therapy. The Swiss company's groundbreaking solutions combine screening, imaging, and analysis to radically advance how scientists study living cells and provide novel biological insights to longstanding questions in medicine such as the mechanisms involved in cancer and neurodegenerative diseases.

Find more information at www.nanolive.ch and follow the company on LinkedIn.

For Media Inquiries:

Nanolive SA
Route de Lully, 5B
1131 Tolochenaz
Switzerland
lookinginsidelife@nanolive.ch